Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.

ABSTRACT:

Background

Osimertinib is a third generation tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR) in lung cancer. However, although this molecule is not subject to some of the resistance mechanisms observed in response to first generation TKIs, ultimately, patients relapse because of unknown resistance mechanisms. New relevant non-small cell lung cancer (NSCLC) mice models are therefore required to allow the analysis of these resistance mechanisms and to evaluate the efficacy of new therapeutic strategies.

Methods

Briefly, PC-9 cells, previously modified for luciferase expression, were injected into the tail vein of mice. Tumor implantation and longitudinal growth, almost exclusively localized in the lung, were evaluated by bioluminescence

SUBMITTER: Jarry U 

PROVIDER: S-EPMC8111918 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature